FDA Approves Piqray-Faslodex Combo for Some Patients with Advanced Breast Cancer
News
Breast cancer patients in the U.S. who are receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-), and have mutated PIK3CA can now be treated with Novartis‘ Piqray (alpelisib) ... Read more